These findings provide further evidence that the anticancer effects of combined treatment of γ-tocotrienol with PPARγ antagonist are mediated through PPARγ-independent mechanisms in +SA PPARγ negative mammary tumor cells. The gene discussed is PPARG; the disease is breast cancer.